The Cypher sirolimus-eluting coronary stent continued to provide clinical benefits compared to a bare metal stent in the E-SIRIUS Trial, which assessed the agent out to five years of follow-up, and showed no differences in safety, according to data presented at the European Society of Cardiology Congress 2007, held in Vienna, Austria.
At year five, the patients in the Cypher stent arm of the study continued to be significantly less likely than the those in the bare metal stent group to need another procedure in the same arterial area (target lesion revascularization). In addition, the investigators found similar rates of myocardial infarction and mortality between the two groups, as well as no significant difference between their rates of stent thrombosis, noted Cordis, the makers of the cardiac device, which is a unit of US health care major Johnson & Johnson.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze